Skip to main content

Table 4 Haematological & Non-haematological toxicity per treatment arm

From: A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

  DC
(n = 67)
D
(n = 65)
DC
(n = 67)
D
(n = 65)
P-value
  GrIII GrIII GrIV GrIV  
  N % N % N % N %  
Neutropenia 7 10.4 3 4.6 4 6.0 1 1.5 0.098
Anaemia 3 4.5 - - - - - - 0.791
Thrombocytopenia 2 3.0 - - - - - - < 0.001
Febrile neutropenia - - - - - - - -  
Nausea - - - - - - - - 0.128
Vomiting - - - - - - - - 0.999
Diarrhoea 2 3.0 1 1.5 1 1.5 - - 0.999
Stomatitis - - - - - - - - 0.027
Constipation - - - - - - - - 0.274
Neuromuscular - - - - - - - - 0.999
Neurosensory - - - - - - - - 0.678
Allergy 2 3.0 - - - - 1 1.6 0.680
Fatigue - - 6 9.2 - - 1 1.5 0.015
Oedema - - - - - - - - 0.680
Other          0.999
  1. P-value for Neutropenia: for grade III/IV vs 0-II between the two groups
  2. P-value for Anaemia: for grade II-IV vs 0/I between the two groups
  3. P-value for Thrombocytopenia: for any grade vs grade O between the two groups